نتائج البحث

Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study

• Authors : Kaeley, GS; Schett, G; Conaghan, PG

Subjects: Medicin och hälsovetenskap

• Source: Rheumatology (Oxford, England). 63(1):41-49

تفاصيل العنوان

Comparison between super-responders and nonsuper-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.

• Authors : Yizhang Liu^{1,2,3,4,5,6,7}; Kun Hu^{1,2,3,4,5,6,7}; Lu Jian^{1,2,3,4,5,6,7}

• Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-8. 8p.

تفاصيل العنوان

p -Cymene and pachymic acid alleviate adalimumab-resistance cell line inflammatory response via inhibiting PI3K/AKT/mTOR signaling pathway.

• Authors : Gu, Jia-Bo¹ (AUTHOR); Wang, Jun¹ (AUTHOR); Yang, Yang¹ (AUTHOR)

• Source: European Journal of Inflammation. 6/4/2024, p1-10. 10p.

تفاصيل العنوان

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.

• Authors : Fleischmann, Roy¹ (AUTHOR) ; Blanco, Ricardo² (AUTHOR); Van den Bosch, Filip³ (AUTHOR)

• Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p599-615. 17p.

تفاصيل العنوان

Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study.

• Authors : Fernández-Cano, María Carmen^1,2 (AUTHOR) ; Fernández-Cano, Antonio Jesús³ (AUTHOR); Martín-Rodríguez, María Mar¹ (AUTHOR)

• Source: Journal of Clinical Medicine. Jan2024, Vol. 13 Issue 2, p556. 16p.

تفاصيل العنوان

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study.

• Authors : Jones, Graeme¹ (AUTHOR); Calao, Miriam² (AUTHOR) ; Begun, Jakob^3,4 (AUTHOR)

Subjects: *INFLAMMATORY bowel diseases; *CROHN'S disease; *PROPORTIONAL hazards models

• Source: PLoS ONE. 6/13/2024, Vol. 19 Issue 6, p1-21. 21p.

تفاصيل العنوان

Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis.

• Authors : Ling, Stephanie F.^1,2 (AUTHOR); Ogungbenro, Kayode³ (AUTHOR); Darwich, Adam S.⁴ (AUTHOR)

• Source: Pharmaceutics. Jun2024, Vol. 16 Issue 6, p702. 13p.

تفاصيل العنوان

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis.

• Authors : Zhdanava, Maryia (AUTHOR); Kachroo, Sumesh (AUTHOR); Shah, Aditi (AUTHOR)

• Source: Patient Preference & Adherence. Apr2024, Vol. 18, p809-820. 12p.

تفاصيل العنوان

Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.

• Authors : Zhe Yu¹; Ling Gao¹; Yinshan Zang¹

• Source: Immunity, Inflammation & Disease. Feb2024, Vol. 12 Issue 2, p1-11. 11p.

تفاصيل العنوان

NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis.

• Authors : Kamel FZ; Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.; Hoseiny HAM

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/genetics ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/genetics

• Source: BMC immunology [BMC Immunol] 2024 Jul 04; Vol. 25 (1), pp. 40. Date of Electronic Publication: 2024 Jul 04.Publisher: BioMed Central Country of Publication: England NLM ID: 100966980 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2172

تفاصيل العنوان